• Publications
  • Influence
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
TLDR
Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study. Expand
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
TLDR
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy. Expand
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
TLDR
There is strong and confirmatory evidence from two large randomized phase III trials to support paclitaxel-cisplatin as the new standard regimen for treatment of patients with advanced ovarian cancer. Expand
Snail, Slug, and Smad‐interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
It was demonstrated previously that the Snail family of transcription factors and Smad‐interacting protein 1 (Sip1) regulate E‐cadherin and matrix metalloproteinase 2 (MMP‐2) expression, cellularExpand
Epithelial–Mesenchymal Transition in Ovarian Carcinoma
TLDR
Current knowledge in EMT related to adhesion, transcriptional regulation and chemoresistance, and their clinical relevance are summarized, as well as the recently observed regulation of EMT by microRNA. Expand
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
TLDR
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy. Expand
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
TLDR
Degree of differentiation should be used in decisions on therapy in clinical practice and in the FIGO classification of stage I ovarian cancer, the most powerful prognostic indicator of disease-free survival. Expand
Epithelial ovarian carcinoma
TLDR
The low survival rate is related to the high proportion of women who have spread of disease beyond the ovaries at diagnosis, according to International Federation of Gynaecological and Obstetrics (FIGO) staging. Expand
Diagnosis and treatment of sarcoma of the uterus. A review
TLDR
There are differences in survival between histological types of US, and tumor-free resection margins at primary surgery are the most important prognostic factor for survival, sarcoma surgery should be centralized. Expand
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.
TLDR
Survival was evaluated in 455 patients with FIGO stage III invasive ovarian cancer managed between 1983 and 1991 and the prognostic significance of clinical and histopathological variables was evaluated. Expand
...
1
2
3
4
5
...